<DOC>
	<DOCNO>NCT00943917</DOCNO>
	<brief_summary>The purpose study determine safety , efficacy tolerability various dos ITCA 650 subject type 2 diabetes .</brief_summary>
	<brief_title>Study ITCA 650 ( Exenatide DUROS ) Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Males female age 1870 year Type 2 diabetes mellitus ≥ 6 month prior Screening Visit 1 On stable ( &gt; 3 month prior Screening Visit 1 ) treatment regimen metformin monotherapy ; Fasting plasma glucose &lt; 240 mg/dL Screening Visit 1 HbA1c ≥ 7 % ≤ 10 % Screening Visit 1 Prior treatment exenatide Treatment follow antidiabetic agent within 3 month prior Screening Visit 1 : TZDs , sulfonylurea , DPP IV inhibitor , acarbose , insulin ( inject inhale ) History type 1 diabetes and/or history diabetic ketoacidosis Body mass index ≥ 40 kg/m2 ; History organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>